Nkarta gets green light from FDA to test NKX019 cell therapy in AAV
The U.S. Food and Drug Administration (FDA) has given Nkarta the green light to launch a clinical trial testing its cell therapy candidate NKX019 in people with ANCA-associated vasculitis (AAV) and other autoimmune disorders. The upcoming multicenter trial, dubbed Ntrust-2, is expected to initially recruit as many as…